HomeCompareSLMCX vs JNJ

SLMCX vs JNJ: Dividend Comparison 2026

SLMCX yields 8.94% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLMCX wins by $16.1K in total portfolio value
10 years
SLMCX
SLMCX
● Live price
8.94%
Share price
$165.72
Annual div
$14.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36.1K
Annual income
$1,570.71
Full SLMCX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — SLMCX vs JNJ

📍 SLMCX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLMCXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLMCX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLMCX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLMCX
Annual income on $10K today (after 15% tax)
$759.75/yr
After 10yr DRIP, annual income (after tax)
$1,335.10/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, SLMCX beats the other by $631.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLMCX + JNJ for your $10,000?

SLMCX: 50%JNJ: 50%
100% JNJ50/50100% SLMCX
Portfolio after 10yr
$28.1K
Annual income
$1,199.24/yr
Blended yield
4.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SLMCX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLMCX buys
0
JNJ buys
0
No recent congressional trades found for SLMCX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLMCXJNJ
Forward yield8.94%3.36%
Annual dividend / share$14.81$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$36.1K$20.0K
Annual income after 10y$1,570.71$827.78
Total dividends collected$12.3K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SLMCX vs JNJ ($10,000, DRIP)

YearSLMCX PortfolioSLMCX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,594$893.82$10,676$355.77+$918.00SLMCX
2$13,374$968.49$11,407$389.39+$2.0KSLMCX
3$15,354$1,044.10$12,198$426.53+$3.2KSLMCX
4$17,549$1,120.28$13,056$467.62+$4.5KSLMCX
5$19,974$1,196.67$13,987$513.12+$6.0KSLMCX
6$22,645$1,272.93$14,998$563.56+$7.6KSLMCX
7$25,579$1,348.74$16,098$619.52+$9.5KSLMCX
8$28,794$1,423.82$17,295$681.69+$11.5KSLMCX
9$32,307$1,497.88$18,599$750.82+$13.7KSLMCX
10$36,139$1,570.71$20,022$827.78+$16.1KSLMCX

SLMCX vs JNJ: Complete Analysis 2026

SLMCXStock

The investment seeks to provide shareholders with capital gain. Under normal market conditions, the fund invests at least 80% of its net assets in securities of technology and information companies. These companies in which the adviser will concentrate are companies operating in the information technology and communications services sectors, applying a global industry classification standard, as may be amended from time to time, to determine industry/sector classifications, as well as other related industries. The fund may invest up to 25% of its net assets in foreign investments. It is non-diversified.

Full SLMCX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this SLMCX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLMCX vs SCHDSLMCX vs JEPISLMCX vs OSLMCX vs KOSLMCX vs MAINSLMCX vs ABBVSLMCX vs MRKSLMCX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.